Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

UCB's Kygevvi wins European Commission approval as first treatment for thymidine kinase 2 deficiency
Small molecule, neurological, mitochondrial disease, thymidine kinase 2 deficiency, pediatric patients - Read more

Sanofi's Rezurock (belumosudil) receives conditional EU approval for chronic graft-versus-host disease after ROCK2 inhibition
Small molecule, autoimmune, ROCK2 inhibitor, chronic graft-versus-host disease, conditional approval - Read more

BMS, Faro partner on multi-year AI clinical trial protocol improvement agreement
Research collaboration, AI/ML, clinical trials, digital health - Read more

Merck & Co., Infinimmune partner on antibody discovery collaboration worth up to $838M in milestones
Research collaboration, autoimmune, antibody, AI/ML, milestone payments - Read more

Shanghai Huaota Biopharmaceutical, Almirall partner on global research and licensing agreement worth up to $340 million
Licensing deal, dermatology, milestone payments, manufacturing - Read more

Boehringer Ingelheim, OpenProtein.AI expand antibody discovery partnership with integrated AI workflows for next-generation therapies
Research collaboration, AI/ML, antibody, drug discovery - Read more

Galapagos, Gilead collaborate on first-in-class T cell engager gamgertamig for autoimmune diseases
Research collaboration, autoimmune, cell therapy, milestone payments - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Enveda reports positive Ph1b results for ENV-294 targeting cellular immune response in atopic dermatitis treatment
Small molecule, autoimmune, atopic dermatitis, molecular glue, LOCKTAC, AI drug discovery - Read more

Aletira Therapeutics launches as first company spun out of Blackbird Laboratories and Johns Hopkins partnership
Gene therapy, strategic, investment, operational - Read more

Ambrosia Biosciences raises $100M Series B, developing oral weight-loss medications
Obesity, small molecule, GLP-1, clinical-stage - Read more

Scala Biodesign raises $16M Series A for protein design platform ScalaOS
Protein design, AI/ML platform, platform technology, therapeutic development - Read more

Avo raises $10M, AI platform streamlining clinical workflows and documentation.
AI/ML platform, clinical workflow, healthcare software, medical documentation - Read more [Paywall]

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B to enter sleep disorder market, challenging Takeda
Small molecule, neurological, strategic, major transaction - Read more

Biogen to acquire Apellis Pharmaceuticals for $5.6B to gain kidney disease expertise and commercial assets
Monoclonal antibody, kidney disease, strategic, major transaction - Read more

Novo Nordisk launches Wegovy subscription program offering patients $249 monthly pricing with multi-month telehealth options
GLP-1 agonist, obesity, strategic, cost reduction, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Astellas lets AviadoBio gene therapy option lapse, returning AVB-101 rights worth $2.2B milestones
Licensing deal, neurological, gene therapy, milestone payments - Read more

PepGen's PGN-EDODM1 shows mixed Ph2 results for myotonic dystrophy type 1 treatment
Oligonucleotide therapy, neurological, antisense oligonucleotide, myotonic dystrophy type 1, RNA splicing correction - Read more

AstraZeneca's efzimfotase alfa (ALXN1850) shows mixed Ph3 results for alkaline phosphatase-targeting hypophosphatasia therapy
Protein therapy, rare disease, enzyme replacement therapy, hypophosphatasia, alkaline phosphatase - Read more

Iterum Therapeutics initiates wind-down after failing to sell antibiotic Orlynvah amid sluggish sales
Antibiotic, infectious disease, operational, financial - Read more

Lipella Pharmaceuticals files for bankruptcy, ending development of mouth inflammation drug LP-10
Liposomal formulation, autoimmune, financial, operational - Read more

Novo Nordisk cuts 400 jobs at troubled Bloomington manufacturing site amid corporate overhaul
GLP-1 agonist, metabolic disease, operational, cost reduction - Read more

IO Biotech files for bankruptcy following FDA refusal to approve cancer vaccine Cylembio after phase 3 failure
Cancer vaccine, oncology, financial, operational - Read more

BASF Pharma Solutions raises API and excipient prices up to 20% citing rising energy costs
API manufacturing, supply chain, operational, cost increase, energy crisis - Read more

FDA flags 76 liver injury cases, 8 deaths linked to Amgen's Tavneos amid withdrawal request
Small molecule, rare disease, regulatory, safety concern - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here